risks

The biggest risk threatening TIS at the moment is if they fail the final approval process....

This would be a death blow for TIS as they really have nothing else to fall back on......

We've all read the most previous announcements indicating quite clearly the positive results from VitroGro.....

However we are all sitting on our hands waiting to see if we pass final approval for sale.....

From Todays Directors Report

" 2. During January 2010 Tissue Therapies executed a contract with Cardiff University for Professor Keith Harding to conduct a human trial of VitroGro? for completion at the end of December 2010.

This clinical trial will be used to produce the final data necessary for the approval of VitroGro? for sale in Europe,
Britian, Canada, Australia and New Zealand, with subsequent rollout planned for the rest of the world. "

This it would appear is the only thing holding this stock back.... Of most concern is the possibility that it fails...

Yes it can work brilliantly but still fail...

This wouldn't be the first time that a sure thing failed at the post????

Any thoughts?????